JP2004508297A - 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 - Google Patents

糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 Download PDF

Info

Publication number
JP2004508297A
JP2004508297A JP2002508433A JP2002508433A JP2004508297A JP 2004508297 A JP2004508297 A JP 2004508297A JP 2002508433 A JP2002508433 A JP 2002508433A JP 2002508433 A JP2002508433 A JP 2002508433A JP 2004508297 A JP2004508297 A JP 2004508297A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
aralkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002508433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508297A5 (fr
Inventor
パウル・デー・ファン・プーレイ
マーク・ディ・エライオン
藤原　俊彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of JP2004508297A publication Critical patent/JP2004508297A/ja
Publication of JP2004508297A5 publication Critical patent/JP2004508297A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002508433A 2000-07-06 2001-07-05 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 Pending JP2004508297A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (fr) 2000-07-06 2001-07-05 Combinaison d'inhibiteurs de fbpase et d'agents antidiabetiques utile pour le traitement du diabete

Publications (2)

Publication Number Publication Date
JP2004508297A true JP2004508297A (ja) 2004-03-18
JP2004508297A5 JP2004508297A5 (fr) 2011-07-07

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002508433A Pending JP2004508297A (ja) 2000-07-06 2001-07-05 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤

Country Status (18)

Country Link
EP (1) EP1372660A2 (fr)
JP (1) JP2004508297A (fr)
KR (1) KR100854851B1 (fr)
CN (2) CN101301294A (fr)
AU (2) AU2001273271B2 (fr)
BR (1) BR0112212A (fr)
CA (1) CA2412142A1 (fr)
CZ (1) CZ20035A3 (fr)
HU (1) HUP0301830A3 (fr)
IL (2) IL153513A0 (fr)
MX (1) MXPA02012713A (fr)
NO (1) NO20030034L (fr)
NZ (1) NZ523227A (fr)
PL (1) PL365779A1 (fr)
RU (1) RU2328308C2 (fr)
SK (1) SK62003A3 (fr)
WO (1) WO2002003978A2 (fr)
ZA (1) ZA200300044B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064744A1 (fr) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Composition medicinale pour le traitement du diabete
WO2007023754A1 (fr) * 2005-08-22 2007-03-01 Metabasis Therapeuticis Inc. MÉDICAMENT CONTENANT L'INHIBITEUR FBPase
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
NZ510308A (en) 1998-09-09 2003-06-30 Metabasis Therapeutics Inc Heteroaromatic alkylene substituted phosphonate derivatives useful as inhibitors of Fructose 1,6-bisphosphatase
US6919322B2 (en) 2000-03-08 2005-07-19 Metabasis Therapeutics, Inc. Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
SI3002283T1 (en) 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
WO1998039342A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
WO1998039343A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs de benzimidazole de fructose-1,6-bisphosphatase
WO1999047549A1 (fr) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
WO2000014095A1 (fr) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs heteroaromatiques de fructose-1,6-biphosphatase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01006511A (es) * 1998-12-24 2004-03-19 Metabasis Therapeutics Inc Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes.
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
WO1998039342A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
WO1998039343A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs de benzimidazole de fructose-1,6-bisphosphatase
WO1999047549A1 (fr) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
WO2000014095A1 (fr) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs heteroaromatiques de fructose-1,6-biphosphatase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
WO2006064744A1 (fr) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Composition medicinale pour le traitement du diabete
WO2007023754A1 (fr) * 2005-08-22 2007-03-01 Metabasis Therapeuticis Inc. MÉDICAMENT CONTENANT L'INHIBITEUR FBPase
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche

Also Published As

Publication number Publication date
NZ523227A (en) 2005-04-29
ZA200300044B (en) 2004-05-06
BR0112212A (pt) 2003-12-30
IL153513A (en) 2014-07-31
HUP0301830A3 (en) 2007-10-29
WO2002003978A2 (fr) 2002-01-17
IL153513A0 (en) 2003-07-06
AU2001273271B2 (en) 2006-01-05
PL365779A1 (en) 2005-01-10
KR100854851B1 (ko) 2008-08-27
CN1599612A (zh) 2005-03-23
AU7327101A (en) 2002-01-21
CA2412142A1 (fr) 2002-01-17
NO20030034D0 (no) 2003-01-03
RU2328308C2 (ru) 2008-07-10
CZ20035A3 (cs) 2003-05-14
CN101301294A (zh) 2008-11-12
KR20030031952A (ko) 2003-04-23
WO2002003978A3 (fr) 2003-10-16
CN100396283C (zh) 2008-06-25
NO20030034L (no) 2003-03-05
MXPA02012713A (es) 2004-09-10
HUP0301830A2 (hu) 2003-11-28
SK62003A3 (en) 2003-09-11
EP1372660A2 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
KR100854851B1 (ko) 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물
KR100689943B1 (ko) 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
CN101827832B (zh) 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK8892002A3 (en) Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CZ283968B6 (cs) Použití sensitizéru insulinu k výrobě prostředku pro léčbu a profylaxi pankreatitidy
EP2351567B1 (fr) Composition pharmaceutique et medicament pour la prevention et le traitement de diabetes ou de l'obesite comprenant comme principe actif, un compose qui inhibe l'activation de dipeptidyl peptidase-iv
US20100056460A1 (en) Combination of organic compounds
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (fr) Combinaisons d'inhibiteurs de la FBPase et de sensibilisateurs à l'insuline, pour le traitement du diabète

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100629

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802